地舒单抗与社区获得性肺炎风险:一项基于人群的队列研究
该研究利用英国初级保健数据库(IQVIA医学研究数据库)开展倾向评分匹配队列研究,比较地舒单抗与阿仑膦酸钠起始治疗的骨质疏松患者(年龄>45岁)发生社区获得性肺炎的风险。地舒单抗组933例,阿仑膦酸钠组4652例,随访5年,两组肺炎发病率分别为72.0(95%CI 60.1-85.7)与75.1(95%CI 69.4-81.2)/1000人年,风险比HR 0.96(95%CI 0.79-1.16)。结论认为地舒单抗不显著增加社区获得性肺炎易感性,可能可安全用于骨质疏松管理。
要点
- 地舒单抗组社区获得性肺炎发病率为72.0/1000人年,阿仑膦酸钠组为75.1/1000人年。
- 地舒单抗与阿仑膦酸钠使用者社区获得性肺炎风险相似(HR 0.96;95%CI 0.79-1.16)。
- 敏感性分析结果一致,HR范围0.82(95%CI 0.65-1.04)至0.99(95%CI 0.81-1.21)。
核心结论
- 地舒单抗不显著增加社区获得性肺炎易感性,可能可安全用于骨质疏松管理。
研究设计与样本
- 基于英国初级保健数据库(IQVIA医学研究数据库)的倾向评分匹配队列研究。
- 研究对象为2010年8月1日至2020年9月17日期间起始地舒单抗或阿仑膦酸钠治疗、年龄大于45岁的骨质疏松患者。
- 采用Cox比例风险模型分析地舒单抗与社区获得性肺炎的关系。
主要发现
- 地舒单抗组933例,阿仑膦酸钠组4652例;匹配人群中平均(SD)年龄77(11)岁,89%为女性,约半数有主要骨质疏松性骨折史。
- 随访5年,社区获得性肺炎每1000人年发病率在地舒单抗组为72.0(95%CI 60.1-85.7),在阿仑膦酸钠组为75.1(95%CI 69.4-81.2)。
- 地舒单抗与阿仑膦酸钠使用者的社区获得性肺炎风险相似(HR 0.96;95%CI 0.79-1.16)。
- 一系列敏感性分析结果保持一致,HR范围为0.82(95%CI 0.65-1.04)至0.99(95%CI 0.81-1.21)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Recent meta-analyses of randomized controlled trials have raised concerns that denosumab might increase the risk of infection. However, data of denosumab on the risk of community-acquired pneumonia are sparse. OBJECTIVE: This work aimed to examine the risk of community-acquired pneumonia in individuals receiving denosumab compared to those receiving alendronate. METHODS: We conducted a propensity score-matched cohort study with a UK primary care database (IQVIA Medical Research Database). We examined the relation of denosumab to community-acquired pneumonia using a Cox proportional hazard model. The study participants were osteoporotic patients older than 45 years who were initiators of denosumab or alendronate from August 1, 2010, to September 17, 2020. The outcome measure was community-acquired pneumonia. RESULTS: Patients treated with denosumab (n = 933) were compared with those treated with alendronate (n = 4652). In the matched population, the mean (SD) age was 77 (11) years, 89% were women, and about half of the study population had a history of major osteoporotic fracture. Over 5 years of follow-up, the incidence of community-acquired pneumonia per 1000 person-years was 72.0 (95% CI, 60.1-85.7) in the denosumab group and 75.1 (95% CI, 69.4-81.2) in the alendronate group. The hazard of community-acquired pneumonia was similar between denosumab and alendronate users (hazard ratio [HR] 0.96; 95% CI, 0.79-1.16). The results remained consistent in a series of sensitivity analyses, with HR ranging from 0.82 (95% CI, 0.65-1.04) to 0.99 (95% CI, 0.81-1.21). CONCLUSION: Denosumab does not significantly increase the susceptibility of community-acquired pneumonia and could possibly be safely used for the management of osteoporosis.
引用
- Lyu H, Zhao S, Li J, et al. Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study. J Clin Endocrinol Metab. 2022. PMID: 35511602. doi:10.1210/clinem/dgac262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。